TransThera Sciences (Nanjing), Inc.
藥捷安康(南京)科技股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2617)

VOLUNTARY ANNOUNCEMENT

FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH NOVEL HORMONAL THERAPY FOR PRETREATED AND PROGRESSED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN CHINA

This announcement is made by TransThera Sciences (Nanjing), Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the "**Board**") of the Company announces that the first patient was recently dosed in the Phase II clinical trial of the Company's core product tinengotinib (Yochanra®, Tinengotinib, TT-00420) in combination with novel hormonal therapy (NHT) for pretreated and progressed metastatic castration-resistant prostate cancer (mCRPC) in China.

This trial is an open-label, multi-center, Phase II clinical study, aimed at evaluating the safety and efficacy of tinengotinib in combination with NHT in patients with pretreated and progressed mCRPC. The primary target population of this trial are patients who have experienced disease progression after receiving prior novel hormonal therapy (including abiraterone and AR inhibitors). The primary endpoints of the trial include safety assessment, the 6-month PFS rate (6mo-PFS), and radiographic progression-free survival (rPFS).

The global market size for mCRPC drugs reached USD16.13 billion in 2025 and is expected to grow to USD28.09 billion by 2032 at a compound annual growth rate of 8.25%. Simultaneously, the domestic market maintains high-speed growth, with the CRPC treatment market size in China reaching RMB19.443 billion in 2025, representing a year-on-year increase of 12.3%, higher than the average growth rate of the overall anti-tumor drug market. The rigid clinical treatment demand continues to be unleashed. Among them, although NHT drugs can significantly prolong the survival of patients and serve as the current first-line core treatment regimen for mCRPC, the vast majority of patients will eventually develop acquired resistance.

Tinengotinib is the world's first and only investigational drug that concurrently inhibits the FGFR/JAK pathways and evidently demonstrates clinical efficacy against mCRPC. It is found in recent studies that activation of the FGFR and JAK pathways promotes the transformation of androgen-sensitive cancer cells into neuroendocrine cancer cells, thereby causing drug resistance. Simultaneous inhibition of the FGFR and JAK pathways can reverse this cell state transition or lineage reprogramming, restoring cancer cells' sensitivity to androgens and re-sensitizing them to the NHT treatment. The tinengotinib monotherapy has demonstrated encouraging antitumor efficacy in patients with mCRPC who have received multiple prior lines of therapy. In addition, the tinengotinib monotherapy for the treatment of mCRPC received Fast Track Designation from the U.S. FDA in June 2025.

About Tinengotinib

Tinengotinib is a self-developed, marketed innovative multi-target small molecule kinase inhibitor targeting FGFR, JAK, VEGFR and Aurora, which exerts antitumor effects by precision targeting, lineage reprogramming and immune activation. Currently, tinengotinib has been approved for marketing in the PRC for its first indication, CCA, and multiple clinical trials have been conducted globally for solid tumors such as CCA, prostate cancer, breast cancer and liver cancer. It has been granted Orphan Drug Designation and Fast Track Designation by the U.S. FDA for the treatment of CCA, and Orphan Drug Designation by the EMA in Europe for the treatment of biliary tract cancers.

Warning under Rule 18A.08(3) of the Listing Rules: There is no assurance that the relevant products will ultimately be successfully developed and marketed by the Company.

By order of the Board
TransThera Sciences (Nanjing), Inc.
Dr. Frank Wu
Chairman and Chief Executive Officer

Hong Kong, 18 September 2026

As at the date of this announcement, the Board comprises: (i) Dr. Frank Wu and Mr. Wu Di as executive directors; (ii) Ms. Jia Zhongxin as a non-executive director; and (iii) Ms. Chui Hoi Yam, Mr. Feng Weibo and Mr. Li Shu Pai as independent non-executive directors.